Related Experiment Video

Updated: Jun 5, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Current directions of biologic therapies in inflammatory bowel disease

Catherine Reenaers1, Edouard Louis, Jacques Belaiche

  • 1Gastroenterology, CHU Sart-Tilman, 4000 Liège, Belgium.

Therapeutic Advances in Gastroenterology
|December 25, 2010
PubMed

Insights

New biologic therapies, including anti-tumor necrosis factor (TNF) and anti-integrin antibodies, offer improved treatment options for inflammatory bowel diseases like Crohn

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) often resistant to conventional treatments.
  • Pathophysiological insights have driven the development of targeted biologic therapies for IBD.
  • Current IBD management faces challenges with conventional therapies' efficacy and side effect profiles.

Purpose of the Study:

  • To review the efficacy and safety of novel biologic therapies for inflammatory bowel diseases.
  • To discuss monoclonal antibodies targeting tumor necrosis factor (TNF) and leukocyte trafficking pathways.
  • To highlight emerging biologic agents and their potential in managing CD and UC.

Main Methods:

  • Review of clinical trial data and scientific literature on biologic therapies for IBD.
  • Analysis of monoclonal antibodies targeting specific inflammatory mediators like TNF, integrins, and cytokines.
  • Comparative assessment of treatment outcomes, including clinical response, remission rates, and safety profiles.

Main Results:

  • Anti-tumor necrosis factor (TNF) monoclonal antibodies (infliximab, adalimumab) demonstrate efficacy in inducing remission in CD and UC.
  • Certolizumab pegol shows short-term efficacy, with long-term data pending.
  • Anti-integrin therapies, such as vedolizumab (anti-α4β7), offer good efficacy and safety, while natalizumab (anti-α4) has safety concerns.
  • Ustekinumab, targeting interleukins 12 and 23, shows promise for CD treatment.

Conclusions:

  • Biologic therapies targeting specific molecular pathways represent a significant advancement in IBD treatment.
  • Anti-TNF and anti-integrin agents provide effective options for managing CD and UC.
  • Ongoing research into novel biologic targets promises further improvements in IBD patient care.
Keywords:
Crohn’s diseaseadalimumabcertolizumabinflammatory bowel diseaseinfliximabnatalizumabulcerative colitisustekinumabvedolizumab

More Related Videos

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...